Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishnu Vijay Vijayan

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Oncoimmunology|September 17, 2024
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacyVishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, Shashi Gujar
ACS Nano|May 8, 2026
Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic ReprogrammingPreethi Gopalakrishnan Nair, Unnikrishnan Babukuttan Sheela, Vishnu Vijay Vijayan, et al.
Seminars in Immunology|May 18, 2026
Dendritic cells as central coordinators of oncolytic virus-induced antitumor immunityEhab M Ezzaldeen, Vishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directionsShashi Gujar, Jonathan G Pol, Vishnu Vijay Vijayan, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|May 10, 2025
Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancerGabriela Maria De Abreu Gomes, Mengnan Xu, Alia Kazim Rizvi Syeda, et al.
Cell Reports|March 21, 2026
Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cellsMichael A Giacomantonio, Vishnu Vijay Vijayan, Preethi G Nair, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Oncoimmunology|September 17, 2024
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacyVishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, Shashi Gujar
ACS Nano|May 8, 2026
Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic ReprogrammingPreethi Gopalakrishnan Nair, Unnikrishnan Babukuttan Sheela, Vishnu Vijay Vijayan, et al.
Seminars in Immunology|May 18, 2026
Dendritic cells as central coordinators of oncolytic virus-induced antitumor immunityEhab M Ezzaldeen, Vishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directionsShashi Gujar, Jonathan G Pol, Vishnu Vijay Vijayan, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|May 10, 2025
Targeting TRPML3 inhibits proliferation and invasion, and enhances doxorubicin sensitivity by disrupting lysosomal acidification and mitochondrial function in triple-negative breast cancerGabriela Maria De Abreu Gomes, Mengnan Xu, Alia Kazim Rizvi Syeda, et al.
Cell Reports|March 21, 2026
Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cellsMichael A Giacomantonio, Vishnu Vijay Vijayan, Preethi G Nair, et al.
Pageof 1